Search results
Results from the WOW.Com Content Network
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [31] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
Even with falling sales, Humira should still rank as the top-selling drug in the world in 2024.
The best-selling drugs list published by Genetic Engineering & Biotechnology News, shows that Humira occupied the #1 position for 2015 (US$14.012 billion) and 2016 (US$16.078 billion) [100] From 2012 until the US patent expired in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had US$16 billion of global sales ...
AbbVie's anti-inflammatory medication Humira, used to treat several indications including the aforementioned rheumatoid arthritis, ranks as one of the best-selling drugs in history. Humira pulled ...
For context, AbbVie’s arthritis and psoriasis treatment, Humira, the world’s best-selling drug for nearly a decade, garnered $20.7 billion in 2021 sales. Merck’s extraordinarily successful ...
This list of top-selling drugs could look drastically different in a few years. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways to ...
This page was last edited on 20 January 2025, at 06:23 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.